PL411561A1 - Profil mikroRNA skojarzony z profilem markerów białkowych krwi jako test wykrywania raka płuca - Google Patents

Profil mikroRNA skojarzony z profilem markerów białkowych krwi jako test wykrywania raka płuca

Info

Publication number
PL411561A1
PL411561A1 PL411561A PL41156115A PL411561A1 PL 411561 A1 PL411561 A1 PL 411561A1 PL 411561 A PL411561 A PL 411561A PL 41156115 A PL41156115 A PL 41156115A PL 411561 A1 PL411561 A1 PL 411561A1
Authority
PL
Poland
Prior art keywords
lung cancer
level
profile
mirna
expression
Prior art date
Application number
PL411561A
Other languages
English (en)
Inventor
Rafał Dziadziuszko
Witold Rzyman
Ewa Szutowicz-Zielińska
Jacek Jassem
Joanna Polańska
Piotr Widłak
Original Assignee
Gdański Uniwersytet Medyczny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gdański Uniwersytet Medyczny filed Critical Gdański Uniwersytet Medyczny
Priority to PL411561A priority Critical patent/PL411561A1/pl
Priority to PCT/PL2016/000028 priority patent/WO2016148593A1/en
Publication of PL411561A1 publication Critical patent/PL411561A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Przedmiotem wynalazku jest metoda predykcyjna do wykrywania i/lub wykluczenia raka płuca, polegająca na pomiarze poziomu ekspresji miRNA i stężenia białek w próbce badanej, obejmująca: - badanie w biologicznej próbce krwi 23 miRNA oraz 6 markerów białkowych, - oznaczenie poziomu ekspresji wskazanych miRNA i stężenia wskazanych białek we krwi, względem poziomu ekspresji wskazanych miRNA, poprzez wyliczenie różnicy pomiędzy poziomem referencyjnym miRNA a zmierzoną wartością ekspresji każdego ze wskazanych miRNA, - oznaczenie i odniesienie stężenia białek do wartości referencyjnej podanej jako wartość górnego poziomu wartości referencyjnych dla danego markera białkowego w populacji osób zdrowych, do którego odnoszone jest jego stężenie w surowicy osoby badanej. Ujawniono również zestaw testowy oraz zastosowanie tej metody do wykrywania raka płuca u osób z grupy wysokiego ryzyka zachorowania na raka płuca.
PL411561A 2015-03-13 2015-03-13 Profil mikroRNA skojarzony z profilem markerów białkowych krwi jako test wykrywania raka płuca PL411561A1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL411561A PL411561A1 (pl) 2015-03-13 2015-03-13 Profil mikroRNA skojarzony z profilem markerów białkowych krwi jako test wykrywania raka płuca
PCT/PL2016/000028 WO2016148593A1 (en) 2015-03-13 2016-03-11 A microrna profile combined with a profile of blood protein markers as a test for the detection of lung cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL411561A PL411561A1 (pl) 2015-03-13 2015-03-13 Profil mikroRNA skojarzony z profilem markerów białkowych krwi jako test wykrywania raka płuca

Publications (1)

Publication Number Publication Date
PL411561A1 true PL411561A1 (pl) 2016-09-26

Family

ID=55795158

Family Applications (1)

Application Number Title Priority Date Filing Date
PL411561A PL411561A1 (pl) 2015-03-13 2015-03-13 Profil mikroRNA skojarzony z profilem markerów białkowych krwi jako test wykrywania raka płuca

Country Status (2)

Country Link
PL (1) PL411561A1 (pl)
WO (1) WO2016148593A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109628597A (zh) * 2019-01-22 2019-04-16 武汉科技大学 一种CRP和miR-365-3p联合检测胃癌的引物、试剂盒及检测方法
WO2024128987A2 (en) * 2022-12-15 2024-06-20 MiRXES Lab Pte. Ltd. Circulating biomarkers for the detection of lung cancer and methods thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10815517B2 (en) * 2009-04-28 2020-10-27 Roche Diagnostics Operations, Inc. Use of DPPIV/seprase as a marker for cancer
EP2336353A1 (en) 2009-12-17 2011-06-22 febit holding GmbH miRNA fingerprints in the diagnosis of diseases
WO2011035433A1 (en) * 2009-09-23 2011-03-31 University Health Network Selected strains on serum-free growth media for proteomics analysis of lung cancer biomarkers
EP2505663A1 (en) 2011-03-30 2012-10-03 IFOM Fondazione Istituto Firc di Oncologia Molecolare A method to identify asymptomatic high-risk individuals with early stage lung cancer by means of detecting miRNAs in biologic fluids
JP2014507160A (ja) * 2011-02-22 2014-03-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． 循環バイオマーカー

Also Published As

Publication number Publication date
WO2016148593A1 (en) 2016-09-22

Similar Documents

Publication Publication Date Title
MX374652B (es) Ensayos para detectar la presencia o la cantidad de un anticuerpo antifármaco.
MX2020009278A (es) Ensayos para detectar la neurodegeneración.
RU2016134839A (ru) Биомаркер и способы для ранней диагностики болезни альцгеймера
ATE554389T1 (de) Apex als marker für lungenkrebs
BR112014006741A2 (pt) método para monitorização, diagnóstico e/ou prognóstico de lesão renal aguda no estágio inicial
ATE536553T1 (de) Verfahren zum nachweis grösserer ungünstiger kardiovaskulärer und zerebrovaskulärer ereignisse
MX383381B (es) Métodos y composiciones para detectar proteínas mal plegadas.
BR112016004320A2 (pt) biossensor, sistema, kit, métodos de determinação ou de identificação e de quantificação de uma concentração de amônia ou íon amônio, de diagnóstico de uma doença metabólica em um sujeito, de determinação da resposta do paciente a uma terapia, de fabricação de um biossensor, de um sistema ou de qualquer tira de teste e de detecção da presença, ausência, ou quantidade de aminoácidos em uma amostra, e, tira de teste
BR112016029521A2 (pt) ?kit, dispositivo e método para a detecção de câncer de estômago?
CY1121916T1 (el) Βιοδεικτες micro-rna για την ταυτοποιηση του κινδυνου και/ή τη διαγνωση του ογκου στον πνευμονα
BR112014026997A2 (pt) técnica e sistema aprimorados de medição de analito
BR112016013976A2 (pt) método para determinar se um indivíduo é afetado por um câncer, método para discriminar entre câncer colorretal e pancreático dentre indivíduos que resultam ser positivos para o método, método para determinar o estágio de um câncer colorretal em um indivíduo afetado e uso de um kit de rt-pcr quantitativo para performar o método
MX2010000971A (es) Sistema y metodos que determinan concentracion de analito utilizando amperometria resuelta en tiempo.
WO2015077382A3 (en) Combined cytology and molecular testing for early detection of esophageal adenocarcinoma
CY1119797T1 (el) Λακτοφερινη για χρηση στη διαγνωση και προγνωση της νοσου alzheimer
BR112016017901A2 (pt) ensaio inovador para detectar periostina humana
TW201621318A (zh) 皮膚黏彈性的標記物及其利用
ATE468535T1 (de) Verwendung von nnmt als marker für lungenkrebs
ATE430936T1 (de) Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
MX2009001070A (es) Uso de proteina con actividad inhibidora de melanoma (mia) como un indicador temprano para la respuesta terapeutica en melanoma.
MX384485B (es) Deteccion temprana de preeclampsia.
PL406989A1 (pl) Profil mikro RNA we krwi jako test wykrywania raka płuca
ATE534037T1 (de) Verwendung des proteins asc als marker für brustkrebs
PL406987A1 (pl) Profil markerów białkowych krwi jako test wykrywania raka płuca
BR112017011724A2 (pt) ensaio para detectar dpp-4 humana